Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc Raises Low End Of Prior FY 2013 Guidance To A Range In Line With Analysts' Estimates; Issues Q3 2013 Guidance In Line With Analysts' Estimates


Wednesday, 31 Jul 2013 09:00am EDT 

Allergan Inc announced that for fiscal 2013, it expects total product net sales between Total product net sales between $6.050 billion and $6.200 billion, Non-GAAP diluted earnings per share to be between $4.72 and $4.76. For the third quarter of 2013, it expects total product net sales between $1.500 billion and $1.575 billion. Non-GAAP diluted earnings per share attributable to stockholders from continuing operations between $1.18 and $1.20. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6.16 billion and EPS of $4.74 for fiscal 2013; revenue of $1.517 billion and EPS of $1.20 for the third quarter of 2013. 

Company Quote

212.745
0.645 +0.30%
26 Nov 2014